Project Grant R01HL181174
Award Date 9/16/25
Completion Date 6/30/30
Dollars Obligated $799K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
- This $834,249 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The study aims to provide long-term data on clinical effectiveness, safety, and patient-reported outcomes to inform treatment selection and guide patient care. It will also utilize...
- This federal Project Grant, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports research to assess the timing and risk of developing Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) and sepsis in children following congenital heart defect (CHD) surgery. The $271,938 award to Vanderbilt University Medical Center (VUMC) will fund a deeper analysis of institutional databases to understand how this syndrome...
- This federal Project Grant award of $193,984 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the interplay between inflammation, angiogenesis, myocardial perfusion, and myocardial function in patients with advanced chronic kidney disease (CKD). The project, conducted by Brigham & Women's Hospital Inc., aims to mechanistically explore cardiovascular health before and after kidney transplantation. Key objectives...
- The University of Alabama at Birmingham (UAB) was awarded a $539,342 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on the circadian mechanisms governing cardiac growth. The project aims to investigate how the cardiomyocyte circadian clock regulates cardiac processes, particularly the branched chain amino acid catabolism and mTOR activation during the active and sleep periods. This research seeks to advance...
- This Project Grant award of $777,258 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to advance the understanding of heart failure in hypertrophic cardiomyopathy (HCM) and evaluate the impact of the cardiac myosin inhibitor mavacamten compared to surgical myectomy. The research, to be conducted by Beth Israel Deaconess Medical Center, Inc. from February 2025 through January 2030, will utilize cardiac magnetic resonance imaging...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Vanderbilt University Medical Center (VUMC) provides $173,352 to conduct research on the molecular characterization of frailty and functional limitations in heart failure with preserved ejection fraction (HFpEF). The key objectives are to measure associations between the human proteome and measures of multi-organ function in HFpEF, and to identify and prioritize...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $194,375 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, Santa Barbara (UCSB) to study the impact of cardiomyopathy-driven extracellular matrix (ECM) remodeling on myocardial viscoelasticity and its effects on cardiomyocyte phenotype. The 24-month project aims to: 1) Determine how cardiomyopathy alters myocardial viscoelasticity, and 2) Assess how matrix viscoelasticity regulates...
- The University of Alabama at Birmingham (UAB) received a $637,732 project grant from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on improving the cardiac microenvironment as a novel strategy against diabetic ischemic heart failure. The project aims to leverage insights from cellular secretome research to transform treatment strategies for diabetic ischemic heart failure. Specifically, the research will investigate how...
- The federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides funding of $158,544 to Vanderbilt University Medical Center (VUMC) from August 1, 2025 to July 31, 2030. The project aims to advance the understanding of clonal hematopoiesis of indeterminate potential (CHIP) and its role in the development of atherosclerotic cardiovascular disease (ASCVD). Specifically, the grant will (1) identify...
- The National Heart Lung and Blood Institute (NHLBI) awarded a $711,039 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital. The award supports research to determine the functions of the cardiac m6A methyltransferases METTL3 and METTL14 in early myocardial development, and whether their dysregulation contributes to the pathogenesis of fetal dilated cardiomyopathy (DCM). The proposed study leverages mouse...